Drug firms colluded to raise price of essential NHS medicine by 1,800 per cent, watchdog finds Collusion by three pharmaceutical firms has resulted in eye-watering price rises for a life-saving drug purchased by the National Health Service, according to provisional findings by the competition watchdog.
In 2016, pharmaceutical giant Aspen made a deal with two other firms to keep them out of the UK market for fludrocortisone, the Competition and Markets Authority (CMA) said on Thursday. Thousands of patients rely on the medicine to treat what is known as Addison’s disease – an insufficient production of certain hormones. The Independent
See also:
In 2016, pharmaceutical giant Aspen made a deal with two other firms to keep them out of the UK market for fludrocortisone, the Competition and Markets Authority (CMA) said on Thursday. Thousands of patients rely on the medicine to treat what is known as Addison’s disease – an insufficient production of certain hormones. The Independent
See also:
- 3 drug firms accused of illegal market sharing Competition and Markets Authority
No comments:
Post a Comment